Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.
- DOI
- 10.1016/j.ard.2026.06.010
- Published
- 2026 Jul 3
- Container
- Annals of the rheumatic diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ard.2026.06.010,
title = {Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.},
author = {Aso K and Matsuzaki K and Saito J and Tarumi M and Fujimoto T and Horita T},
year = {2026},
journal = {Annals of the rheumatic diseases},
doi = {10.1016/j.ard.2026.06.010},
url = {https://doi.org/10.1016/j.ard.2026.06.010}
}RIS
TY - JOUR TI - Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma. AU - Aso K AU - Matsuzaki K AU - Saito J AU - Tarumi M AU - Fujimoto T AU - Horita T PY - 2026 JO - Annals of the rheumatic diseases DO - 10.1016/j.ard.2026.06.010 UR - https://doi.org/10.1016/j.ard.2026.06.010 ER -
APA
K, A., K, M., J, S., M, T., T, F., & T, H. (2026). Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.. Annals of the rheumatic diseases. https://doi.org/10.1016/j.ard.2026.06.010
Source records
- pubmed · retrieved 2026-09-26T15:37:41.783Z